JPMorgan Chase Trims Stake in Bioventus Inc.

The financial giant reduced its position in the medical device company by over 50% in the third quarter.

Apr. 12, 2026 at 9:04am

Got story updates? Submit your updates here. ›

A high-contrast black and white close-up image of the intricate gears and circuits of a financial trading terminal, representing the heavy industrial nature of institutional investing.An extreme close-up of the complex inner workings of institutional finance reveals the tangible machinery powering major investment decisions.Durham Today

JPMorgan Chase & Co. lowered its stake in Bioventus Inc. (NASDAQ:BVS) by 52.9% during the third quarter, according to a recent SEC filing. The fund now owns 114,777 shares of the company's stock, down from 243,710 shares previously held.

Why it matters

This reduction in JPMorgan's position in Bioventus could signal a shift in the investment firm's outlook on the medical device company's prospects. As a major institutional investor, JPMorgan's moves are closely watched by the market.

The details

According to the filing, JPMorgan Chase sold 128,933 shares of Bioventus stock during the third quarter. The firm now owns approximately 0.14% of Bioventus, down from 0.30% previously. Bioventus is a global medical device company focused on orthobiologic solutions for musculoskeletal conditions.

  • JPMorgan Chase reduced its Bioventus stake during the third quarter of 2026.

The players

JPMorgan Chase & Co.

A major global financial services firm and one of the largest institutional investors in the United States.

Bioventus Inc.

A medical device company specializing in orthobiologic solutions for musculoskeletal conditions.

Got photos? Submit your photos here. ›

The takeaway

This reduction in JPMorgan's Bioventus stake suggests the investment firm may have a less optimistic outlook on the medical device company's future performance compared to previous assessments. However, without further details, it's difficult to determine the specific reasons behind JPMorgan's portfolio adjustment.